=Tandem Diabetes Care (TNDM) sees Q4 revs above consensus

Tandem Diabetes Care sees Q4 revs above consensus; sees FY18 revs in line 

• Co issues upside guidance for Q4 (Dec), sees Q4 (Dec) revs of $39-40 mln vs. $34.18 mln Capital IQ Consensus Estimate.
• Co issues in-line guidance for FY18 (Dec), sees FY18 (Dec) revs of $132-140 mln vs. $135.78 mln Capital IQ Consensus Estimate. "With our robust product pipeline and increasing number of customer renewal opportunities, growth remains a top focus, but equally so is closely managing our expenses as we leverage our existing infrastructure in 2018,"